A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors

Inclusion Criteria:

- Advanced solid tumor

- Cancer for which standard therapies do not exist or are no longer effective

- Life expectancy of > 3 months

- Adequate bone marrow, liver, and kidney function

- Willing to use accepted method of contraception during the course of the study

- Negative pregnancy test (females)

- Written informed consent

Exclusion Criteria:

- Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)

- Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment

- Investigational drug within 30 days of the start of treatment

- Subjects with known brain metastasis

- Uncontrolled medical disorder such as infection or cardiovascular disease

- Subjects known to be HIV positive

- Pregnant or breastfeeding women